Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016090
Abstract: Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with… read more here.
Keywords: myeloid leukemia; acquired mutations; therapy; acute myeloid ... See more keywords